Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BLFS 
BioLife Solutions Inc (BLFS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/04/2025: BLFS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $32.1
1 Year Target Price $32.1
| 7 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -26.39% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.24B USD | Price to earnings Ratio - | 1Y Target Price 32.1 |
Price to earnings Ratio - | 1Y Target Price 32.1 | ||
Volume (30-day avg) 9 | Beta 1.93 | 52 Weeks Range 19.10 - 29.62 | Updated Date 12/5/2025 |
52 Weeks Range 19.10 - 29.62 | Updated Date 12/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.38 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-06 | When - | Estimate -0.0113 | Actual 0.042 |
Profitability
Profit Margin -3.2% | Operating Margin (TTM) -0.32% |
Management Effectiveness
Return on Assets (TTM) -0.73% | Return on Equity (TTM) -5.25% |
Valuation
Trailing PE - | Forward PE 1000 | Enterprise Value 1169979653 | Price to Sales(TTM) 12.42 |
Enterprise Value 1169979653 | Price to Sales(TTM) 12.42 | ||
Enterprise Value to Revenue 11.68 | Enterprise Value to EBITDA 67.84 | Shares Outstanding 48148046 | Shares Floating 40796321 |
Shares Outstanding 48148046 | Shares Floating 40796321 | ||
Percent Insiders 2.05 | Percent Institutions 103.5 |
Upturn AI SWOT
BioLife Solutions Inc
Company Overview
History and Background
BioLife Solutions, Inc. was founded in 1998 and is a leading developer, manufacturer, and supplier of biopreservation media for cells, tissues, and organs. It has grown through organic expansion and acquisitions to provide a comprehensive portfolio of biopreservation tools and services.
Core Business Areas
- Biopreservation Media: Development, manufacture, and sale of proprietary biopreservation media products such as CryoStoru00ae and HypoThermosolu00ae.
- Freezers and Thawing Systems: Manufacture and supply of controlled-rate freezers and automated thawing systems used in cell and gene therapy.
- Biologic Transportation and Storage: Provides solutions for the temperature-controlled storage and transport of biological materials, including liquid nitrogen freezers and cloud-based monitoring systems.
- Cell Processing: Offering cell washing instruments to streamline cell processing for cell and gene therapy clients.
Leadership and Structure
The leadership team includes Roderick de Greef (CEO), Troy Wichterman (CFO), and Todd Berard (COO). The organizational structure is typical of a publicly traded company, with functional departments like R&D, Manufacturing, Sales & Marketing, and Finance.
Top Products and Market Share
Key Offerings
- CryoStoru00ae: A line of cryopreservation freeze media used to protect cells during freezing and thawing. It is the market leader. The competitors are STEMCELL Technologies, Corning. No explicit market share data is available. However, BioLife Solutions holds a dominant market position in this space. Revenue is the main driver for growth
- HypoThermosolu00ae: A hypothermic preservation media used to store cells at refrigerated temperatures. The competitors are STEMCELL Technologies, Corning. No explicit market share data is available. Revenue is the main driver for growth.
- evou00ae Smart Shipper: A platform for temperature-controlled biologics shipping. The competitors are Modality Solutions, Cryoport. No explicit market share data is available. Revenue is the main driver for growth.
Market Dynamics
Industry Overview
The biopreservation market is growing rapidly due to the expansion of cell and gene therapy, regenerative medicine, and drug discovery. Key drivers include increasing demand for cell-based therapies and growing R&D investments in life sciences.
Positioning
BioLife Solutions is a leader in the biopreservation market, holding a strong position due to its proprietary media formulations, broad product portfolio, and established customer base. Its competitive advantage lies in its brand recognition, product quality, and comprehensive solutions.
Total Addressable Market (TAM)
The estimated TAM is multiple billions of dollars. BioLife Solutions is well-positioned with its established products and expanding portfolio to capture a significant portion of this market.
Upturn SWOT Analysis
Strengths
- Proprietary media formulations
- Strong brand recognition
- Established customer base
- Comprehensive product portfolio
- Leadership in biopreservation
Weaknesses
- Dependence on cell and gene therapy market growth
- Potential for increased competition
- High valuation relative to earnings
Opportunities
- Expansion into new geographic markets
- Development of new biopreservation technologies
- Strategic acquisitions
- Growth in cell and gene therapy market
Threats
- Economic downturn affecting R&D spending
- Regulatory changes
- Emergence of disruptive technologies
- Increased competition from larger companies
Competitors and Market Share
Key Competitors
- CYRX
- HOLX
- PRLB
Competitive Landscape
BioLife Solutions has a strong position due to its proprietary media and focus. Competitors often have a broader product portfolio but less focus on biopreservation.
Major Acquisitions
SAVSU Technologies
- Year: 2020
- Acquisition Price (USD millions): 93
- Strategic Rationale: Expanded BioLife Solutions' cold chain management capabilities and provided access to cloud-based monitoring technology.
Global Cooling
- Year: 2021
- Acquisition Price (USD millions): 150
- Strategic Rationale: Strengthened BioLife Solutions' offering of controlled-rate freezers and thawing systems.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by organic growth and acquisitions.
Future Projections: Future growth is projected to continue, driven by the cell and gene therapy market. Analyst estimates vary, but generally reflect optimism.
Recent Initiatives: Recent initiatives include acquisitions of companies in the biopreservation and cell processing space.
Summary
BioLife Solutions is a key player in the growing biopreservation market, driven by the expansion of cell and gene therapies. They have a strong product portfolio and customer base. However, it is important that they keep a close eye on competition and economic downturns, as well as regulatory changes. Their continued success relies on innovation and adaptation in a fast-paced industry. They are highly dependent on the growth of cell and gene therapies.
Similar Stocks
Sources and Disclaimers
Data Sources:
- BioLife Solutions Investor Relations
- SEC Filings (10-K, 10-Q)
- Analyst Reports
- Company Press Releases
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market conditions and company performance can change rapidly. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BioLife Solutions Inc
Exchange NASDAQ | Headquaters Bothell, WA, United States | ||
IPO Launch date 1989-11-22 | CEO & Chairman Mr. Roderick de Greef | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 159 | Website https://www.biolifesolutions.com |
Full time employees 159 | Website https://www.biolifesolutions.com | ||
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.